Experience with Ceftriaxone in the Treatment of Pulmonary Infections

DOI: http://dx.doi.org/10.5915/17-1-12717 This paper describes the experience with a new third generation cephalosporin, Ceftriaxone, in the treatment of 60 patients with bacterial pulmonary infection. The unique pharmacokinetics of Ceftriaxone allow its usage twice a day in contrast to the 4 to 6 times a day for comparable antibiotics, with potential cost savings. Administered twice a day the overall cure rate was 94% with no serious side effects. A brief review of the clinical application of Cephalosporins in the treatment of infections is included. Presented at the 17th Annual Convention of the Islamic Medical Association in St. Louis, Missouri, August 10-12, 1984